Celgene (CELG) Return on Equity ROE from the third quarter 2019 to third quarter 2018 and annually, average high and low, overall ranking from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Celgene Corp  (NASDAQ: CELG)

Celgene's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Celgene in the third quarter 2019?
Celgene Corp achieved a return on average equity (ROE) of 64.5 % in its third quarter 2019, this is above CELG's average return on equity of 32.78%.
Celgene Corps equity during the 12 months ending in the third quarter 2019 are valued at $9 billion

ROE fell compared to the second quarter 2019, despite the net income growth of 7.64% from the second quarter 2019.

Within the Major Pharmaceutical Preparations industry 10 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 664, from total ROE ranking in the second quarter 2019 at 793.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Equity Change 148.7 % 193.03 % 57.87 % -10.98 % -
Y / Y Net Income Change 56.28 % 50.33 % 82.62 % - 9.51 %
Net Income (TTM) in Millions 5,880 5,271 4,745 4,046 2,892
Return On Equity (TTM) 64.5 % 72.11 % 83.92 % 82.47 % 56.75 %
CELG's Total Ranking # 664 # 793 # 1045 # 0 # 0
Equity (TTM) in Millions 12,087 10,051 8,165 6,161 4,860
Seq. Equity Change 20.26 % 23.1 % 32.53 % 26.77 % 41.69 %
Seq. Net Income Change 7.64 % 1.68 % 43.99 % -0.83 % 3.54 %

Back to CELG Management Effectiveness >> CELG's 5 Years Annual ROE >> Compare CELG ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 11
Sector # 21
Overall # 664

Return On Equity Statistics
High Average Low
184.54 %
32.78 %
-55.34 %
(Sep 30 2017)   (March 31, 2008)





CELG Annual Return On Equity (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015		 (FY 2014)
(Dec. 31, 2014)
Total Equity in Millions 6,161 6,921 6,599 5,919 6,525
Y / Y Equity Change -10.98 % 4.87 % 11.49 % -9.28 % 16.72 %
Net Income in Millions 4,046 2,940 1,999 1,602 2,000
Y / Y Net Income Change 37.62 % 47.06 % 24.79 % -19.9 % 37.93 %
Return On Equity 65.67 % 42.48 % 30.29 % 27.07 % 30.65 %

Back to CELG Management Effectiveness >> CELG's 5 Years Annual ROE >> Compare CELG ROE to its Competitors




Annual Roe Comment
In 2018 ROE improved to 65.67 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CELG's' Return on Equity at Yahoo Finance
CELG's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CELG's Competitors
Subscribers only: Roe for Celgene's Suppliers
Subscribers only: Return On Equity for CELG's Customers




Companies with similar Return On Equity at Sep 30 2019, within Healthcare Sector ROE
Eli Lilly And Company  160.61 %
Orgenesis Inc   130.66 %
Nrc Health  130.25 %
Integrated Biopharma Inc  123.39 %
Mettler toledo International Inc   104.97 %
Waters Corporation  71.93 %
Amgen Inc   71.62 %
Zynex inc   71.37 %
Molecular Templates Inc   70.94 %
Ligand Pharmaceuticals Incorporated  67.27 %
Oxford Immunotec Global Plc  65.30 %
Celgene Corp  64.50 %
Palatin Technologies Inc   63.20 %
Zoetis Inc   60.93 %
Oramed Pharmaceuticals Inc  58.95 %
Iveric Bio Inc   58.48 %
Viskase Holdings inc   54.57 %
Arena Pharmaceuticals Inc   52.86 %
Harrow Inc   51.16 %
3m Company  48.98 %
Siga Technologies Inc  47.82 %
Strongbridge Biopharma plc  45.77 %
Remedent Inc   43.59 %
Vertex Pharmaceuticals Inc  43.50 %
Adaptive Biotechnologies Corporation  42.61 %
Exelixis Inc   42.49 %
Biogen Inc   40.11 %
Lantheus Holdings Inc   39.71 %
Vanda Pharmaceuticals Inc   38.90 %
Contrafect Corporation  38.39 %

Date modified: 2026-09-08T15:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.